^
Contact us  to learn more about
our Premium Content:  News alerts, weekly reports and conference planners
BIOMARKER:

INPP4B overexpression

i
Other names: INPP4B, Inositol Polyphosphate-4-Phosphatase Type II B, Inositol Polyphosphate-4-Phosphatase Type II B, Inositol Polyphosphate 4-Phosphatase Type II, Inositol Polyphosphate 4-Phosphatase II
Entrez ID:
Related biomarkers:
15d
Preliminary Study of the Role of INPP4B in Promoting Colorectal Cancer Metastasis and the Mechanisms Involved (PubMed, Sichuan Da Xue Xue Bao Yi Xue Ban)
INPP4B is highly expressed in CRC tissues and significantly correlated with lymph node metastasis, neural invasion, and patient prognosis. MMP7 may mediate the role of INPP4B in promoting CRC cell migration and invasion.
Journal
|
INPP4B (Inositol polyphosphate-4-phosphatase type II B) • MMP7 (Matrix metallopeptidase 7)
|
INPP4B overexpression
10ms
Role of INPP4B in the proliferation, migration, invasion, and survival of human endometrial cancer cells. (PubMed, Histol Histopathol)
The current study suggested that INPP4B could be a suppressor in endometrial cancer progression and might be a target for endometrial cancer treatment. Also, INPP4B might serve as a predictor of chemosensitivity determination.
Journal
|
INPP4B (Inositol polyphosphate-4-phosphatase type II B)
|
INPP4B overexpression • INPP4B mutations
over1year
Tumor Suppressor Role of INPP4B in Chemoresistant Retinoblastoma. (PubMed, J Oncol)
No changes in AKT signaling were discernible, but p-SGK3 levels increased following INPP4B overexpression, indicating a potential regulation of SGK3 signaling in etoposide-resistant RB cells. RNAseq analysis of INPP4B overexpressing, etoposide-resistant RB cell lines revealed differentially regulated genes involved in cancer progression, mirroring observed in vitro and in vivo effects of INPP4B overexpression and strengthening INPP4B's importance for cell growth control and tumorigenicity.
Journal
|
CASP3 (Caspase 3) • INPP4B (Inositol polyphosphate-4-phosphatase type II B) • CASP7 (Caspase 7)
|
INPP4B overexpression
|
etoposide IV
almost2years
The FDA-Approved Drug Pyrvinium Selectively Targets ER Breast Cancer Cells with High INPP4B Expression. (PubMed, Cancers (Basel))
Here, using cell viability assays, we report that INPP4B overexpression does not affect the sensitivity of ER breast cancer cells to standard-of-care treatments including the anti-estrogen 4-hydroxytamoxifen (4-OHT) or the PI3Kα inhibitor alpelisib. Using 3D culture models, we demonstrated that pyrvinium selectively reduced the size of INPP4B-overexpressing ER breast cancer spheroids in the presence and absence of 4-OHT. These findings suggest that repurposing pyrvinium as a Wnt inhibitor may be an effective therapeutic strategy for human ER breast cancers with high INPP4B levels.
FDA event • Journal
|
ER (Estrogen receptor) • PIK3CA (Phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit alpha) • INPP4B (Inositol polyphosphate-4-phosphatase type II B)
|
ER positive • INPP4B overexpression
|
tamoxifen • Piqray (alpelisib)
2years
INPP4B inhibits glioma cell proliferation and immune escape via inhibition of the PI3K/AKT signaling pathway. (PubMed, Front Oncol)
Collectively, these data support that INPP4B may inhibit glioma progression, and particularly, glioma's immune escape. Thus, INPP4B may constitute a valuable target for glioma treatment.
Journal • PD(L)-1 Biomarker • IO biomarker
|
INPP4B (Inositol polyphosphate-4-phosphatase type II B)
|
PD-L1 expression • INPP4B overexpression
over2years
ELOVL2 restrains cell proliferation, migration, and invasion of prostate cancer via regulation of the tumor suppressor INPP4B. (PubMed, Cell Signal)
Our findings suggest that ELOVL2 might be a prognostic biomarker and therapeutic target for prostate cancer.
Journal
|
INPP4B (Inositol polyphosphate-4-phosphatase type II B)
|
INPP4B overexpression
almost3years
NanoString Digital Molecular Profiling of Protein and microRNA in Rhabdomyosarcoma. (PubMed, Cancers (Basel))
This study highlights the utility of NanoString digital profiling methods in RMS, where it can detect distinct molecular signatures with the expression of signaling pathways and microRNAs from FFPE tumor tissue that may help identify prognostic biomarkers of interest. The overexpression of INPP4B and miR-3144-3p, miR-612, miR-302d-3p, miR-421, miR-548y and miR-548ar-5p may be associated with worse overall survival in ERMS and SRMS.
Journal • PARP Biomarker
|
EGFR (Epidermal growth factor receptor) • NF1 (Neurofibromin 1) • BCL2L1 (BCL2-like 1) • INPP4B (Inositol polyphosphate-4-phosphatase type II B) • CASP9 (Caspase 9) • MIR612 (MicroRNA 612)
|
INPP4B overexpression
3years
INPP4B exerts a dual role in gastric cancer progression and prognosis. (PubMed, J Cancer)
These findings suggested that the expression of INPP4B in GC is lower than that in normal tissues. Based on stratification survival analysis and in vitro cell experiments, INPP4B may play dual roles as an oncogene and tumour suppressor gene in different tissue grades and clinical stages.
Journal
|
INPP4B (Inositol polyphosphate-4-phosphatase type II B)
|
INPP4B overexpression
over3years
Expression and functional characterization of INPP4B in gallbladder cancer patients and gallbladder cancer cells. (PubMed, BMC Cancer)
These findings suggested that INPP4B may play a dual role in the prognosis of GBC depending on the degree of differentiation and that INPP4B might act as an oncogene in gallbladder cancer cells.
Clinical • Journal
|
INPP4B (Inositol polyphosphate-4-phosphatase type II B)
|
INPP4B overexpression